Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia
Information source: New York University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Tachycardia, Ventricular
Intervention: Remifentanil (Drug)
Phase: N/A
Status: Completed
Sponsored by: New York University School of Medicine Official(s) and/or principal investigator(s): Misha Kogan, MD, Principal Investigator, Affiliation: NYU School of Medicine
Summary
Determine effects of remifentanil conscious sedation in patients undergoing
Electrophysiological (EP) studies for the ablation of idiopathic ventricular tachycardia
and/or persistent frequent premature ventricular contractions (PVCs) of non-ischemic origin
Clinical Details
Official title: Remifentanil IV PCA for Ablation of Idiopathic Ventricular Tachycardia
Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Inhibition of Idiopathic Ventricular TachycardiaPVC Suppression With Remifentanil Sedation
Detailed description:
The purpose of the study is to determine the effects of remifentanil conscious sedation in
patients undergoing Electrophysiological (EP) studies for the ablation of idiopathic
ventricular tachycardia and/or persistent frequent PVCs of non-ischemic origin.
Remifentanil is an analgesic- synthetic opiate with an very short half life. It is rapidly
broken down by enzymes in the blood and is ideally suited for continuous sedation. The
effect is practically eliminated within 5 minutes after the intravenous sedation is stopped.
You are being asked to participate in this study because you are already scheduled to
undergo EP studies under the care of your cardiologist for the ablation of idiopathic
ventricular tachycardia and/or persistent frequent PVCs of non-ischemic origin.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients scheduled to undergo EP studies for the ablation of idiopathic ventricular
tachycardia and/or persistent frequent PVCs of non-ischemic origin
- Patients between 18 and 65
- ASA 1-3
Exclusion Criteria:
- ASA 4 and 5
- Age 18 and 65
Locations and Contacts
NYU Langone Medical Center, New York, New York 10016, United States
Additional Information
Related publications: Garofalo NA, Teixeira-Neto FJ, Schwartz DS, Vailati Mdo C, Steagall PV. Effects of the opioid remifentanil on the arrhythmogenicity of epinephrine in halothane-anesthetized dogs. Can J Vet Res. 2008 Jul;72(4):362-6.
Starting date: July 2011
Last updated: May 9, 2015
|